Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
21 March, 2018 12:21 IST
Piramal Enterprises concludes acquisition of drug portfolio from Mallinckrodt
Source: IRIS | 20 Mar, 2017, 10.28AM
Comments  |  Post Comment

Piramal Enterprises, one of India's largest diversified companies with a presence in pharmaceutical, financial services, announced that its wholly owned Critical Care subsidiary in the UK has completed its acquisition of a portfolio of drugs for spasticity and pain management from Mallinckrodt LLC (Mallinckrodt).

As indicated in the Press Release dated January 30, 2017, the acquisition was for a cash consideration of USD 171 million and up to an additional USD 32 million payable depending on financial performance of the acquired assets over the next three years.

The portfolio acquired includes Gablofen (baclofen), a severe spasticity management product, which is currently marketed in the United States, and two pain management products, which are currently under development. Gablofen has also been approved for launch in eight European markets.

Gablofen is the only intrathecal baclofen drug available in vials and pre-filled syringes, which are preferred by users over the competing products available in ampoules. The pain management drugs under development are also for intrathecal administration. In the twelve months ending September 30, 2016, the acquired portfolio generated revenues of USD 44.6 million.

Shares of the company gained Rs 9.25, or 0.5%, to trade at Rs 1,871.90. The total volume of shares traded was 217 at the BSE (10.17 a.m., Monday).

Piramal Enterprises Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Security Code type    into this box
Company Update
Ashok Leyland bags orders for 2100 Buses from Institute of Road Transport, Tamil Nadu - 21-Mar-2018 10:17
Suzlon designs and produces India's longest wind turbine blade of 63 meters - 21-Mar-2018 10:11
Mphasis partners with Plug and Play - 21-Mar-2018 09:55
Force Motors signs JV agreement with MTU Friedrichshafen GmbH - 21-Mar-2018 09:48
TCS partners with Saudi Real Estate Refinance Company - 21-Mar-2018 09:44
GE Power India bags contract worth Rs 3.09 bn - 21-Mar-2018 09:40
Alembic Pharm intimates of USFDA inspection of facility at Panelav - 21-Mar-2018 09:37
Mahindra & Mahindra partners with Standard Chartered - 20-Mar-2018 12:36
BHEL commissions 1st unit of Kishanganga hydro-electric project - 20-Mar-2018 10:12
Suzlon wins two projects of 300 MW and 200 MW each under SECI bid - 20-Mar-2018 10:08
Granules India receives approval for Metformin ER tablets - 20-Mar-2018 10:05
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer